GuillainBarre Syndrome Diagnostics Market

Guillain-Barre Syndrome Diagnostics Market Size

The global Guillain-Barre syndrome diagnostics market size was valued at USD 148.3 million in 2024 and is expected to reach USD 196.7 million in 2034, growing at a CAGR of 2.9% from 2025 to 2034. Guillain-Barre Syndrome (GBS) diagnostics refers to the diagnostic tests and procedures that are used to detect as well as confirm the presence of GBS, a rare autoimmune disorder in which a person’s immune system attacks the peripheral nerves, leading to muscle weakness. Severe cases of this syndrome are quite rare, but they can lead to total paralysis.

The increasing rate of Guillain-Barre Syndrome (GBS), which is expected to reach USD 963.1 million by 2032, is worsening the need for sophisticated diagnostic methods. The syndrome caused by infections is often followed by acute even muscular paralysis and calls for early and precise diagnosis for optimal treatment. Accessibility to healthcare in both developing and developed countries is often worsened due to delays in diagnosis as well as lack of sufficient neurological testing equipment which increases the burden of GBS.

Based on the data from International Journals of Molecular Sciences, the global incidence of 0.9 to 1.2 cases for every 100,000 people in a year and has certain seasonal and geographical patterns due to infections such as Campylobacter jejuni. The market is also undergoing transformation due to the rise in demand for innovative diagnostic aids, in addition to the standard nerve conduction studies and biomarker-based tests that ensure early treatment and positive results for the patients.

Moreover, the global surge in the elderly demographic is shifting its focus towards the demand for Guillain-Barre syndrome diagnostics. The United Nations (UN) estimates that the world population aged 65 years and above is expected to reach 1.6 billion by 2050, which is nearly double the 761 million from 2021. Moreover, according to the National Institutes of Health (NIH), in elderly patients, the rate of GBS cases has been estimated to be 2.66 per 100,000 individuals, which is higher than the younger demographic at 0.75, which correlates to the elder segment of the population experiencing higher incidence rates. This points to an increase of somewhere around 20% for every 10-year increase. Thus, as older population is more vulnerable to developing autoimmune diseases such as GBS, the diagnostics market for this disease is expected to flourish in near future.

 Guillain-Barre Syndrome Diagnostics Market Trends

• The invention of biomarker-based diagnostic tests is augmenting the accuracy and timeliness with which GBS can be identified. New anti-ganglioside antibodies are being studied as potential novel biomarkers that could improve accuracy while decreasing the need for lumbar punctures or electromyography. For example, some researchers aim to create blood assays for biomarker detection that would identify GBS at its earliest stages for prompt treatment.
  
• AI is progressively being incorporated into the diagnosis of GBS and other peripheral nervous system disorders. With the help of AI, diagnosing GBS becomes easier, as more intricate datasets derived from nerve conduction studies (NCS) and electromyography (EMG) are processed and analyzed for underlying GBS markers that are often easy to miss. This development’s goal is to improve diagnosis in terms of accuracy, efficiency, and speed for more timely care.
  
• The need for faster and portable diagnostic services is growing in order to provide healthcare providers the ability to diagnose GBS in different settings, such as emergency departments and outpatient clinics. This is especially useful in low-resource areas. Deymed Diagnostic, for instance, has developed portable versions of their neurodiagnostic testing devices, allowing more people to access the compact EMG and NCS devices.
  
• Manufacturers are developing cost-effective, single-use diagnostic kits to minimize contamination risks and improve operational efficiency in hospitals and clinics. Disposable electrode sets for NCS and EMG are gaining popularity, reducing the need for frequent device sterilization. For instance, Cadwell Industries, Inc. has introduced disposable nerve conduction electrodes to enhance safety and convenience in clinical settings.
  

Guillain-Barre Syndrome Diagnostics Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on test type, the market is segmented into lumbar puncture, nerve conduction, electromyography, and other test types. The global market for Guillain-Barre syndrome diagnostics was valued at USD 144.7 million in 2023. The lumbar puncture segment dominated the market with the largest revenue of USD 66.3 million in 2024.

• The segment held largest market share as lumbar puncture, also known as spine, tap, is indicated in every case of suspected GBS. The clinical diagnosis of this rare disease needs to be confirmed by cerebrospinal fluid (CSF) analysis and nerve conduction studies.
  
• A lumbar puncture is performed in the lumbar region, in one’s lower back. It analyses the cerebrospinal fluid, thus critical for the diagnosis of the disease. In the acute stage of GBS, CSF analysis is important as it shows albuminocytologic dissociation, which further shows increased protein in the CSF (>0.55 g/L) without an increase in the white blood cells. The rise in the CSF protein is believed to be due to the extensive inflammation of the nerve roots.
  
• Moreover, the increasing incidence of GBS is also contributing to the increase of this segmental growth. Furthermore, the diagnostic test is a minimally invasive which allows to remove a small portion of the CSF for testing, making it a convenient and preferred option by the patients.

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the Guillain-Barre syndrome diagnostics market is segmented into hospitals and clinics, diagnostic laboratories, and other end users. Hospitals and clinics segment accounted for the largest revenue share of 62.1% in 2024.

• The segment dominated the market due to the rising number of GBS diagnostic procedures performed in these facilities. Specialized neurology clinics and general hospitals are the main GBS diagnosing and management centers where lumbar punctures, nerve conduction studies, and electromyography (EMG) are performed by qualified professionals. The sophisticated diagnostic devices, coupled with professional healthcare providers and comprehensive patient management, sustains the supremacy of this segment.
  
• Moreover, growth in hospital admissions for other neurologic disorders and further development of diagnostic facilities in hospitals are also fueling the market.
  
• For instance, the National Institute of Neurological Disorders and Stroke (NINDS) has been sponsoring research aimed at enhancing GBS diagnosis and treatment algorithms for use in wards to ensure improved patient handling and prompt disease resolution.

Looking for region specific data?

Download Free PDF

The U.S. Guillain-Barre syndrome diagnostics market revenue has increased considerably from USD 48.8 million in 2023 and is expected to grow significantly, reaching USD 65.7 million by 2034.

• The increasing prevalence of the GBS in the U.S. is impacting quality of life of the residents. For instance, according to the Centers for Disease Control and Prevention (CDC), it is estimated that between 3,000 and 6,000 new cases are reported annually in the country.
  
• In addition to this, the U.S. has an increasing aging population, which is expected to contribute to the market growth in the forecast period. According to the Population Reference Bureau, the number of individuals of 65 years and older is projected to rise from 58 million in 2022 to 82 million by 2050.
  

Europe: The UK Guillain-Barre syndrome diagnostics market is projected to experience steady growth between 2025 and 2034.

• The number of cases of this rare disease are increasing along with the growing elderly population in the UK. According to the UK government, it is estimated that the incidence of GBS in the UK population is at 2 per 100,000 per year and increases with age.
  
• Further, as of December 2021, there have been 472 reports of this rare disease after the AstraZeneca vaccination and 27 reports of Miller Fisher syndrome, which is a variant of GBS.
  
• Such statistics are expected to increase the demand of diagnostic solutions in near future.
  

Asia Pacific: Japan Guillain-Barre syndrome diagnostics market is poised to witness lucrative growth between 2025 – 2034.

• Japan observes a massive aging society; according to data from Statista, as of November 2023, approximately 36.35 million people in Japan were estimated to be over 65 years of age. The GBS is expected to be affecting men aged 50 or more at a greater rate in comparison to others.
  
• Therefore, it is expected that an aging society will require a strong diagnostics sector in the near future and hence the market of Guillain-Barre syndrome diagnostics in the country is expected to rise.
  

Middle East and Africa: The Guillain-Barre syndrome diagnostics market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.

• Saudi Arabia is also experiencing an aging population. For instance, the number of people aged 60 and above is expected to rise five times from 2 million (5.9% of the total population) in 2020, reaching 10.5 million by 2050.
  
• Thus, an aging society is expected to experience an increase in the demand for Guillain-Barre syndrome diagnostics in coming years.
  

Guillain-Barre Syndrome Diagnostics Market Share

Natus Medical Incorporated, Nihon Kohden Corporation, Cadwell Industries, Medtronic plc, and Neurosoft comprise the top 5 market players of the GBS diagnostics market. They account for approximately 50% of revenue share in this market. These companies are determined to enhance the accuracy of GBS diagnostics by advancing neurodiagnostic technologies and expanding their product lines through continuous R&D efforts. They are also forming strategic partnerships with other research and healthcare institutions to improve their market share. In addition, new market entrants such as Deymed Diagnostic, Alpine Biomed, and EMS Biomedical are investing in portable neurodiagnostic systems, AI-based solutions to improve GBS diagnostic efficiency and accessibility, to gain competitive edge against other players in the market. Such initiatives assure more competition in the market and better the health of the patients.

 Guillain-Barre Syndrome Diagnostics Market Companies

Some of the eminent market participants operating in the Guillain-Barre syndrome diagnostics industry include:

• Alpine Biomed
• Avanos 
• Bionen Medical Devices
• Cadwell Industries
• Cardinal Health
• Clarity Medical
• Deymed Diagnostic
• EMS Biomedical
• Medtronic
• Natus Medical Incorporated
• Neurosoft
• Nihon Kohden
• Rochester Electro-Medical
  
• Natus Medical Incorporated actively contributes to the distribution network of GBS diagnostics and the company already has global reach. It provides neurodiagnostic solutions like electrodiagnostic and neuromonitoring devices, which makes sure that aids for diagnosing GBS are available through their strong distribution channels.
  
• Nihon Kohden Corporation holds a strong position in neurodiagnostics through its sophisticated EMG and nerve conduction study systems. For instance, the company has been able to market the Neuropack series that is used widely in the assessment of neuromuscular disorders including GBS, thus consolidating the firm’s position in the neurophysiology diagnostics market.
  
• Cadwell Industries, Inc. boasts a complete line of instruments and systems for diagnostic neurophysiology. The Sierra Summit EMG/NCS/EP system offered by the company employs sensitive analysis of the GBS patients, thus helping in the timely diagnosis of the disease. Innovative and clinically accurate solutions from this company has earned them a position in the market of GBS diagnostics.
  

Guillain-Barre Syndrome Diagnostics Industry News:

• In March 2023, Hansa Biopharma, a leader in enzyme innovation for uncommon immunological diseases, reported that it has completed enrollment for its phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS). The company anticipated sharing top-line results in the latter half of the year.
  

The Guillain-Barre syndrome diagnostics market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Test Type

• Lumbar puncture
• Nerve conduction
• Electromyography
• Other test types

Market, By End Use

• Hospitals and clinics
• Diagnostic laboratories
• Other end use

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands 
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE